Health Trials

Resectable Hepatocellular Carcinoma

4

Review clinical trials related to Resectable Hepatocellular Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)

The purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC

Participants needed: 90
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Zhongshan HospitalUpdated: Jul 20, 2026
Eligibility criteria

Written informed consent shall be obtained prior to any trial-related procedures... [+10]

Histologically or cytologically confirmed tumors containing components of fibrol... [+15]

Read more
Status: Recruiting

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.

Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Fundacion Clinic per a la Recerca BiomédicaUpdated: Jul 8, 2026Locations: 12
Eligibility criteria

Signed Informed Consent Form. [+25]

Presence of extrahepatic disease or macrovascular invasion. [+48]

Read more
Status: Not yet recruiting

THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).

Participants needed: 60
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of Texas Southwestern Medical CenterUpdated: Jul 7, 2026Locations: 1
Eligibility criteria

Diagnosis of HCC confirmed by histology or according to the American Association... [+18]

Presence of extrahepatic extension of disease [+24]

Read more
Status: Recruiting

Neoadjuvant Triple Therapy for Resectable HCC

This study is a single-arm, multi-center, prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (triple therapy) in patients with resectable hepatocellular carcinoma (HCC). The study plans to enroll 20 patients. The primary endpoints are major pathological response (MPR) rate and safety, while the secondary endpoints are recurrence-free survival (RFS), objective response rate (ORR), R0 resection rate, and overall survival (OS).

Participants needed: 20
Trial details
Age: 18-75Biological sex: AllType: ObservationalSponsor: Fujian Provincial HospitalUpdated: Oct 15, 2024Locations: 6Duration: 3 Years
Eligibility criteria

Voluntarily join the study and sign the informed consent form. [+10]

Tumor rupture with bleeding or suspected abdominal cavity metastasis. [+11]

Read more